Article Text

Download PDFPDF
The Associations of Genetic Variants in E-cadherin Gene With Clinical Outcome of Epithelial Ovarian Cancer
  1. Wang Juan, MM,
  2. Kang Shan, PhD,
  3. Wang Na, MD,
  4. Zhou Rong-Miao, PhD and
  5. Li Yan, MD
  1. * Department of Obstetrics and Gynecology, Hebei Medical University, Fourth Hospital; and
  2. Department of Molecular Biology, Hebei Cancer Institute, Shijiazhuang, China.
  1. Address correspondence and reprint requests to Kang Shan, PhD, Department of Obstetrics and Gynecology, Hebei Medical University, Fourth Hospital, Jiankanglu 12, Shijiazhuang 050011, China. E-mail: ksjq62cn{at}


Objective The E-cadherin protein plays major roles in tumor progression, invasion, and metastasis. Polymorphisms located in the E-cadherin gene (CDH1) may contribute to increased risks of specific cancers. In this study, we evaluated the associations between genetic variants in CDH1 and the clinical outcomes of patients with epithelial ovarian cancer (EOC).

Materials and Methods We assessed the −160C/A and −347G/GA polymorphisms in the promoter region, as well as the 3′-UTR +54C/T polymorphism of E-cadherin, in 257 patients with EOC by ligase detection reaction–polymerase chain reaction.

Results Multivariate analysis showed that patients with EOC with the CDH1 −347GA/GA genotype had shorter progression-free survival and overall survival (hazard ratio [HR], 2.16; 95% confidence interval [CI], 1.06–4.40 and HR, 2.06; 95% CI, 1.01–4.19, respectively) compared to those carrying the G/G genotype. Likewise, the patients with the CDH1 −160A/A genotype had a shorter progression-free survival than those with the C/C genotype (HR, 4.12; 95% CI, 1.43–111.88). No significant association was detected between the CDH1 3′-UTR +54C/T polymorphism and survival of the patients with EOC.

Conclusions The CDH1 −347GA/GA and −160A/A genotypes may be prognostic markers that can help to identify patients at increased risk of invasive/metastatic cancer in northern China.

  • E-cadherin polymorphisms
  • Epithelial ovarian cancer
  • Clinical outcome

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.